findmyKOL

Carl Regillo, MD

Enriched profile

Chief, Retina Service, Wills Eye Hospital; Professor of Ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University · Sidney Kimmel Medical College at Thomas Jefferson University

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Plymouth Meeting, PA · Northeast · United StatesSpecialtyOphthalmologyFocusRetinal Diseases and Treatments+4
Active KOLLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Carl Regillo is Chief, Retina Service, Wills Eye Hospital; Professor of Ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University at Sidney Kimmel Medical College at Thomas Jefferson University. OpenAlex indexes 407 publications with 14,493 citations (h-index 58); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

Carl Regillo, MD, is Chief, Retina Service, Wills Eye Hospital at Sidney Kimmel Medical College at Thomas Jefferson University / Wills Eye Hospital. The public record shows 407 publications with 14,493 citations (h-index 58), centered on Retinal Diseases and Treatments, Retinal and Macular Surgery, Intraocular Surgery and Lenses. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 38 companies.

  • Most recent indexed publication: 2026 · Journal of vitreoretinal diseases
  • Top research focus: Retinal Diseases and Treatments
  • 5 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 38 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Macular Degeneration (AMD)2 trialsEpiretinal Membrane1 trialDiabetic Complications1 trialDiabetic Retinopathy / DME1 trialDiabetic Retinopathy1 trialGeographic Atrophy1 trialAtrophy1 trialRetinal Vein Occlusion1 trial

Research focus

OpenAlex concept fingerprint
Retinal Diseases and TreatmentsRetinal and Macular SurgeryIntraocular Surgery and LensesRetinal and Optic ConditionsRetinal Imaging and Analysis

Drugs & molecules

across trials, industry payments and publications
Susvimogeneric · RanibizumabClinical trials—Industry payments30Publications6Izervaygeneric · Avacincaptad pegolClinical trials—Industry payments13Publications1Eyleageneric · AfliberceptClinical trials—Industry payments8Publications4Xiperegeneric · TriamcinoloneClinical trials—Industry payments11Publications1Beovugeneric · BrolucizumabClinical trials—Industry payments5Publications1Syfovregeneric · PegcetacoplanClinical trials—Industry payments20Publications—Yutiqgeneric · FluocinoloneClinical trials—Industry payments18Publications—Ozurdexgeneric · DexamethasoneClinical trials—Industry payments14Publications—VorolanibClinical trials—Industry payments13Publications—Vabysmogeneric · FaricimabClinical trials—Industry payments8Publications—EYLEA HDClinical trials—Industry payments4Publications—Tyrvayageneric · VareniclineClinical trials—Industry payments3Publications—

Works with

trial sponsors and companies reporting payments
EyePoint Pharmaceuticals US, Inc.Clinical trials—Industry payments38Apellis Pharmaceuticals, Inc.Clinical trials—Industry payments37Genentech USA, Inc.Clinical trials—Industry payments30Bausch & Lomb Americas Inc.Clinical trials—Industry payments15Genentech, Inc.Clinical trials—Industry payments12Boehringer Ingelheim International GmbHClinical trials—Industry payments10Astellas Pharma US IncClinical trials—Industry payments9Janssen Global Services, LLCClinical trials—Industry payments8Ocular Therapeutix, Inc.Clinical trials—Industry payments8Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments8Alcon Vision LLCClinical trials—Industry payments6Coherus Biosciences Inc.Clinical trials—Industry payments6F. Hoffmann-La Roche AGClinical trials—Industry payments6Abbvie Inc.Clinical trials—Industry payments5Astellas Pharma Global DevelopmentClinical trials—Industry payments5Vertex Pharmaceuticals IncorporatedClinical trials—Industry payments5Alcon Research LLCClinical trials—Industry payments4Allergan, Inc.Clinical trials—Industry payments4BioCryst Pharmaceuticals, Inc.Clinical trials—Industry payments4Novartis Pharmaceuticals CorporationClinical trials—Industry payments3Oyster Point Pharma, Inc.Clinical trials—Industry payments3Carl Zeiss Meditec, Inc.Clinical trials—Industry payments2Harrow Eye, LLCClinical trials—Industry payments2Hexal AGClinical trials—Industry payments2Kala Pharmaceuticals, Inc.Clinical trials—Industry payments2Merck Sharp & Dohme LLCClinical trials—Industry payments2Novartis Pharma AGClinical trials—Industry payments2Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments2Sanofi Us Services Inc.Clinical trials—Industry payments2Alimera Sciences, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
407publications

Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.

14,493citations

Total citations across indexed works.

58h-index

Hirsch index (OpenAlex). i10-index 177.

Clinical & industry

trials, payments and federal funding
5clinical trials

Investigator role on registered studies.

View trials ↓
38companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:

All 5 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

38 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 76 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    78.4%
    Antineovascularisation agents69.9%
    Faricimab-svoa100%
    Part B, office-administered≥75 patients
    Complement Inhibitor8%
    Avacincaptad pegol100%
    Part B, office-administered≥43 patients

    + 6 more classes in this area

  • Cancer & immunology

    18.9%
    Complement Inhibitor12.7%
    Pegcetacoplan100%
    Part B, office-administered≥53 patients
    Vascular Endothelial Growth Factor Inhibitor6.2%
    Aflibercept99%Eylea1%
    Part D + Part B<11 patients

  • Dermatology

    2.6%
    Corticosteroid2.6%
    Triamcinolone acetonide100%
    Part B, office-administered≥12 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Most-cited works

by citation count (OpenAlex)
  1. 01
    Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies
    Article1,329 citations2014
    doi.org ↗
  2. 02
    Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
    Article862 citations2008
    doi.org ↗
  3. 03
    Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
    Article590 citations2014
    doi.org ↗
  4. 04
    Genetic variants near <i>TIMP3</i> and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration
    Article518 citations2010
    doi.org ↗
  5. 05
    Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial
    Article363 citations2016
    doi.org ↗
All 407 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Allen C. Ho125Jason Hsu117Omesh P. Gupta68Sunir J. Garg62J.F. Vander48Yoshihiro Yonekawa45Anthony Obeid40Mitchell S. Fineman38Marc J. Spirn37Allen Chiang34Richard Kaiser34Gary C. Brown31Joseph I. Maguire29Dean Eliott28Ashish Sharma27Antonio Capone27Daniel P. Joseph26Arunan Sivalingam24Matthew R. Starr24Charles C. Wykoff21David S. Boyer21Ajay E. Kuriyan21Michael J. Ammar21Ehsan Rahimy21Baruch D. Kuppermann21Kevin J. Blinder20Pravin U. Dugel20Francesco Bandello20Nilesh Kumar19Nikulaa Parachuri19Taku Wakabayashi19Khan Ma18Michael A. Klufas18Raziyeh Mahmoudzadeh18Claire Ryan18Geoffrey G. Emerson18Luv Patel17Mirataollah Salabati16Jeffrey S. Heier16Nora J. Forbes16

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/carl-regillo-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/carl-regillo-md-0364a24

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Carl-Regillo-2158251123

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • Facebook

    facebook.com/willseyehospital/posts/watch-dr-carl-regillo-chief-of-the-retina-service-at-wills-eye-hospital-shares-g/1156144899852443

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
  • Instagram

    instagram.com/p/DNjsAKASzWl

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • Instagram

    instagram.com/wills_eye/reel/DA1PtYWNxwy

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
  • Other

    asrs.org/find-a-specialist/profile/15/Carl-D-Regillo

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org ↗
  • X / Twitter

    x.com/Wills_Eye/status/1634302355834535936

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • X / Twitter

    x.com/Wills_Eye/status/1843347640366539159

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Vitreoretinal Fellowship

    Wills Eye Hospital

    1994
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Board Certified

    American Board of Ophthalmology

    1993
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Ophthalmology Residency

    Wills Eye Hospital

    1992
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • MD

    Harvard Medical School

    1988
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗

Editorial & leadership roles

journal and society appointments
  • Secretary

    The Retina Society

    2027
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinasociety.org ↗
  • Scientific editorial board

    American Journal of Ophthalmology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Scientific editorial board

    Review of Ophthalmology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Scientific editorial board

    Current Opinion in Ophthalmology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Scientific editorial board

    Yearbook of Ophthalmology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Scientific editorial board

    Retinal Physician

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Scientific editorial board

    Retina Today

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Fellow

    American College of Surgeons (FACS)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Active member

    American Academy of Ophthalmology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Active member

    The Macula Society

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Active member

    American Society of Retina Specialists

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Former Chairman

    American Academy's Basic and Clinical Science Course (BCSC) Retina Section committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Former Chairman

    Wills Eye Institutional Review Board

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Founder and former Director

    Wills Eye Clinical Retina Research Unit

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Former Wills Retina Fellowship Program Director
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗
  • Former examiner

    American Board of Ophthalmology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Partner/attending physician

    Mid Atlantic Retina

    1998
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →midatlanticretina.com ↗
  • Wills Eye Surgical Network - Main Line

    100 Presidential Blvd., Suite 200, Bala Cynwyd, PA 19004 (additional practice location)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →willseye.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.